Personalized Cancer Vaccine Reports Positive Phase 3 Melanoma Result

Merck and Moderna Report Positive Phase 3 Results for Personalized Melanoma Treatment

Merck and Moderna shared the news on August 19, 2026. They said the Phase 3 trial met its main goals. The study involved high-risk melanoma after surgery. The companies reported a benefit from the combined treatment. Intismeran autogene is made for one patient. It was used with KEYTRUDA, also called pembrolizumab. The combo beat KEYTRUDA alone on two disease control measures.

The result may point to a new path after surgery. It applies to melanoma with a high risk of return. However, the companies have released only top-line findings. Detailed safety data, effect sizes, and full analysis remain pending peer-reviewed publication.

Understanding the Key Measures

The INTerpath-001 trial tracked two outcomes that measure how well the treatment controls melanoma after surgery.

Recurrence-free survival (RFS) measures the time after treatment during which patients remain free of any melanoma recurrence. Cancer may return at the first site. It may return in nearby lymph nodes. It may also return far away. This is a broad measure of cancer control.

Distant metastasis-free survival (DMFS) focuses on whether cancer spreads to distant organs and tissues. Metastasis means cancer has spread far from its first site. Cancer cells may move through blood or lymph. They can then form a new tumor. DMFS tracks whether patients stay free of this dangerous spread.

Both measures track disease control after surgery. One tracks return. The other tracks distant spread.

What Is Intismeran Autogene?

Intismeran autogene is built uniquely for each patient using information from their own tumor. The process starts with removed tumor tissue. A lab looks for gene changes in that tumor. Those changes help make the therapy personal.

These mutation details are used to create a personalized mRNA-based neoantigen therapy tailored to that individual's tumor profile. The goal is to train the immune system. It may then spot cells with those tumor changes. This could matter for cells left after surgery. It could also matter if cancer returns.

Pembrolizumab removes some immune system brakes. Intismeran gives a signal tied to one tumor. The study paired these two ideas. This dual approach aims to improve the body's ability to control high-risk melanoma after surgery.

Trial Design and Population

INTerpath-001 is a randomized, placebo- and active-comparator controlled, triple-masked Phase 3 trial. Patients with surgically removed high-risk stage IIB through stage IV cutaneous melanoma were enrolled. Stage IIB and later melanoma can return after surgery. This risk is why care after surgery matters.

Participants were randomly assigned to receive either intismeran autogene plus pembrolizumab or placebo plus pembrolizumab. The study asks one clear question. Does the personal therapy add a benefit beyond pembrolizumab alone?

What the Companies Reported

Merck and Moderna announced the result on August 19, 2026. They said the trial met its main endpoints. The companies indicated positive results in both recurrence-free survival and distant metastasis-free survival. They have not yet released specific numbers, effect sizes, or safety details in their top-line summary.

The full data are not public. Effect sizes are not public. Detailed harm rates are not public. Group results and overall survival are also unknown. These details typically appear in peer-reviewed publications after company announcements.

What Remains Unclear

Several important questions cannot be answered from the top-line announcement alone:

• How much does the combination reduce recurrence or metastasis risk compared to pembrolizumab alone?
• What is the full safety profile, including frequency and severity of side effects?
• Do results differ meaningfully across patient groups, such as by stage or age?
• Does the treatment extend overall survival—how long patients live after diagnosis?
• What do independent peer reviewers conclude when they examine the data?

These answers require a full data release and independent review.

What Patients Should Do Now

If you have melanoma, speak with your cancer care team. Ask about the choices that are approved now. Do not change or delay current treatment based on this announcement. Your cancer doctor knows your case. That doctor can explain if new research may apply.

For detailed trial information, visit ClinicalTrials.gov (NCT05933577). The joint company announcement is available at BusinessWire.

Medical Information Disclaimer

This article is for informational purposes only and does not constitute medical advice. It reflects data and announcements from the trial sponsors as of the publication date. Research findings are subject to change upon peer review and detailed publication. Always consult a qualified healthcare provider before making medical decisions.

Key Trial Terms in Plain English

Top-line result

A short report from the trial sponsors. It gives the main result. Full data come later.

Recurrence-free survival

Time without the cancer returning. Death also counts in this measure.

Distant metastasis

Cancer spread to a far part of the body.

Personalized therapy

A treatment built from changes found in one person's tumor.

Adjuvant treatment

Care given after surgery. Its goal is to lower the risk of return.

Comparator group

The group used for a fair test. Here, both groups received pembrolizumab.

What the Top-Line Release Does Not Show

A positive headline is only a first look. The joint release does not give several facts needed for a full review.

• The size of the benefit for each endpoint.
• The confidence range around that result.
• Detailed side effect and treatment stop rates.
• Results for age, stage, and other subgroups.
• A final answer on overall survival.
• A peer-reviewed report with the full methods and data.

Those details may change how doctors judge the result. They also matter for safety, access, and future approval review.

Study Design at a Glance

This was a large Phase 3 trial. It tested care after melanoma surgery. The study did not test a store-bought vaccine.

• The registry lists 1,089 planned participants.
• All participants had high-risk cutaneous melanoma.
• Their tumors had been removed by surgery.
• Both groups received pembrolizumab, also called KEYTRUDA.
• One group also received intismeran autogene.
• The other group received a matched placebo.
• The trial used random assignment for a fair test.
• Patients and outcome reviewers were masked to assignment.
• The main endpoint tracked cancer return or death.
• Another endpoint tracked spread to distant parts of the body.

The companies say both endpoints were met. That is good news. It does not tell us the size of the gain.

The full report must show the numbers. It must also show harms. Doctors need both before they can weigh benefit and risk.